Aliases & Classifications for Cerebral Palsy

MalaCards integrated aliases for Cerebral Palsy:

Name: Cerebral Palsy 37 12 72 49 50 36 28 51 40 3 14 69
Infantile Cerebral Palsy 12 69
Cerebral Palsy, Mixed 69
Mixed Cerebral Palsy 49
Palsy Cerebral 72

Classifications:



External Ids:

Disease Ontology 12 DOID:1969
ICD10 32 G80 G80.9
ICD9CM 34 343.8
MeSH 41 D002547
NCIt 46 C34460
KEGG 36 H01097

Summaries for Cerebral Palsy

NINDS : 50 The term cerebral palsy refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement, muscle coordination, and balance.CP affects the part of the brain that controls muscle movements.  The majority of children with cerebral palsy are born with it, although it may not be detected until months or years later. The early signs of cerebral palsy usually appear before a child reaches 3 years of age. The most common are a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a “scissored” gait; and muscle tone that is either too stiff or too floppy. Other neurological symptoms that commonly occur in individuals with CP include seizures, hearing loss and impaired vision, bladder and bowel control issues, and pain and abnormal sensations. A small number of children have CP as the result of brain damage in the first few months or years of life, brain infections such as bacterial meningitis or viral encephalitis, or head injury from a motor vehicle accident, a fall, or child abuse. The disorder isn't progressive, meaning that the brain damage typically doesn't get worse over time. Risk factors associated with CP do not cause the disorder but can increase a child's chance of being born with the disorder.CP is not hereditary.

MalaCards based summary : Cerebral Palsy, also known as infantile cerebral palsy, is related to spastic cerebral palsy and inherited congenital spastic tetraplegia, and has symptoms including sleeplessness, myokymia and vertigo/dizziness. An important gene associated with Cerebral Palsy is ADD3 (Adducin 3), and among its related pathways/superpathways are GABAergic synapse and Vesicle-mediated transport. The drugs Dexmedetomidine and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include Blood and Umbilical Cord, and related phenotypes are behavior/neurological and homeostasis/metabolism

NIH Rare Diseases : 49 Cerebral palsy refers to a group of neurological disorders that can affect the brain and/or spinal cord. Signs and symptoms generally appear during infancy or early childhood and vary based on the type of cerebral palsy (spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy), the severity of the condition and which area(s) of the brain are affected. Common features include a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a "scissored" gait; and muscle tone that is either too stiff or too floppy. Cerebral palsy is caused by abnormal brain development or damage to the developing brain. Most of these problems occur as the baby grows in the womb; however, they can happen at any time during the first 2 years of life. There is no cure for cerebral palsy, but treatment is available to alleviate some symptoms. This may include physical, occupational, and speech therapy; certain medications; surgery; and/or devices (i.e. braces, wheelchairs) to aid in mobility. Last updated: 11/18/2015

MedlinePlus : 40 Cerebral palsy is a group of disorders that affect a person's ability to move and to maintain balance and posture. The disorders appear in the first few years of life. Usually they do not get worse over time. People with cerebral palsy may have difficulty walking. They may also have trouble with tasks such as writing or using scissors. Some have other medical conditions, including seizure disorders or mental impairment. Cerebral palsy happens when the areas of the brain that control movement and posture do not develop correctly or get damaged. Early signs of cerebral palsy usually appear before 3 years of age. Babies with cerebral palsy are often slow to roll over, sit, crawl, smile, or walk. Some babies are born with cerebral palsy; others get it after they are born. There is no cure for cerebral palsy, but treatment can improve the lives of those who have it. Treatment includes medicines, braces, and physical, occupational and speech therapy. NIH: National Institute of Neurological Disorders and Stroke

Disease Ontology : 12 A brain disease that is caused by damage to the motor control centers of the developing brain during pregnancy, during childbirth or after birth, which affects muscle movement and balance.

Wikipedia : 72 Cerebral palsy (CP) is a group of permanent movement disorders that appear in early childhood. Signs and... more...

Related Diseases for Cerebral Palsy

Diseases related to Cerebral Palsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 377)
# Related Disease Score Top Affiliating Genes
1 spastic cerebral palsy 34.1 F5 GAD1 PLP1
2 inherited congenital spastic tetraplegia 33.1 ADD3 GAD1 KANK1
3 hereditary spastic paraplegia 51 32.3 AP4B1 AP4S1
4 spastic paraplegia 50, autosomal recessive 32.2 ADD3 AP4B1 AP4M1 AP4S1
5 chorioamnionitis 30.4 IL1B IL6 TNF
6 eclampsia 29.9 F2 F5 MTHFR TNF
7 gingivitis 29.9 IL1B IL6 TNF
8 thrombosis 29.8 F2 F5 MTHFR
9 pyelonephritis 29.7 IL1B IL6 TNF
10 schizencephaly 29.6 COL4A1 F5 MTHFR
11 juvenile rheumatoid arthritis 29.6 IL1B IL6 TNF
12 pre-eclampsia 29.5 F2 F5 IL6 MTHFR
13 porencephaly 29.5 COL4A1 F2 F5 MTHFR
14 stroke, ischemic 29.5 APOE F2 F5 MTHFR
15 pneumonia 29.3 IL1B IL6 MBL2 TNF
16 multiple sclerosis 28.9 APOE IL1B IL6 PLP1 TNF
17 cerebral palsy, ataxic, autosomal recessive 12.7
18 spastic diplegia cerebral palsy 12.5
19 dyskinetic cerebral palsy 12.5
20 cerebral palsy, spastic quadriplegic, 1 12.4
21 mixed cerebral palsy 12.4
22 cerebral palsy, spastic quadriplegic, 2 12.3
23 cerebral palsy, spastic quadriplegic, 3 12.3
24 spastic quadriplegia 12.2
25 spastic hemiplegia 12.2
26 spastic diplegia 12.2
27 cerebral palsy athetoid 12.2
28 spastic monoplegia 12.0
29 spasticity 11.5
30 periventricular leukomalacia 11.5
31 intellectual disability - athetosis - microphthalmia 11.4
32 swallowing disorders 11.3
33 spastic paraplegia 47, autosomal recessive 11.3
34 spastic paraplegia 52, autosomal recessive 11.3
35 hypertonia 11.2
36 dysphagia 11.2
37 neonatal stroke 11.2
38 developmental coordination disorder 11.2
39 foot drop 11.2
40 hypotonia 11.2
41 cerebellar ataxia, mental retardation, and dysequilibrium syndrome 1 11.2
42 kernicterus 11.2
43 infantile hypotonia 11.2
44 spastic paraplegia 51, autosomal recessive 11.2
45 cerebritis 11.1
46 spastic paraplegia 20, autosomal recessive 11.1
47 spastic paraplegia 2, x-linked 11.1
48 suprabulbar paresis, congenital 11.0
49 parkinsonism-dystonia, infantile 11.0
50 fetal methylmercury syndrome 11.0

Comorbidity relations with Cerebral Palsy via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Cerebral Palsy:



Diseases related to Cerebral Palsy

Symptoms & Phenotypes for Cerebral Palsy

UMLS symptoms related to Cerebral Palsy:


sleeplessness, myokymia, vertigo/dizziness, involuntary movements, abnormality of extrapyramidal motor function, asterixis, muscle fibrillation, chronic pain, tremor, torticollis, syncope, seizures, sciatica, pain, muscle rigidity, headache, dystonia, back pain, athetosis

MGI Mouse Phenotypes related to Cerebral Palsy:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10 APOE PLP1 ATL1 COL4A1 TNF F2
2 homeostasis/metabolism MP:0005376 9.97 AP4M1 MTHFR APOE PLP1 COL4A1 TNF
3 nervous system MP:0003631 9.73 APOE PLP1 COL4A1 TNF F2 F5
4 skeleton MP:0005390 9.28 MTHFR APOE PLP1 TNF F2 GAD1

Drugs & Therapeutics for Cerebral Palsy

Drugs for Cerebral Palsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 176)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 5311068 56032 68602
2
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Levodopa Approved Phase 4 59-92-7 6047
5
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-84-3 187
6
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1 1134-47-0 2284
7
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 7487-88-9 24083
8
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
11
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
12 Adrenergic Agents Phase 4,Phase 1
13 Adrenergic Agonists Phase 4,Phase 1
14 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 1
15 Adrenergic alpha-Agonists Phase 4,Phase 1
16 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
17 Analgesics, Non-Narcotic Phase 4,Phase 3
18 Anesthetics Phase 4,Phase 3,Phase 2
19 Anesthetics, General Phase 4
20 Anesthetics, Inhalation Phase 4
21 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
22 Hypnotics and Sedatives Phase 4
23 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
24 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
25 Platelet Aggregation Inhibitors Phase 4
26 Autonomic Agents Phase 4,Phase 3,Phase 1
27 Carbidopa, levodopa drug combination Phase 4
28 Dihydroxyphenylalanine Phase 4
29 Dopamine Agents Phase 4
30 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
31 abobotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1
32 Botulinum Toxins Phase 4,Phase 2,Phase 3,Phase 1
33 Botulinum Toxins, Type A Phase 4,Phase 2,Phase 3,Phase 1
34 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1
35 Neuromuscular Agents Phase 4,Phase 2,Phase 3,Phase 1
36 onabotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1
37 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
38 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
39 calcium channel blockers Phase 4,Phase 3,Phase 2
40 Calcium, Dietary Phase 4,Phase 3,Phase 2
41 Tocolytic Agents Phase 4,Phase 3,Phase 2
42 Epoetin alfa Phase 4,Phase 3,Phase 2,Phase 1 113427-24-0
43 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
44 incobotulinumtoxinA Phase 4,Phase 3,Phase 2
45 Anesthetics, Local Phase 4
46 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
47 Anesthetics, Intravenous Phase 4
48 calcium heparin Phase 4
49 Acidophilus Nutraceutical Phase 4
50 Sunflower Nutraceutical Phase 4

Interventional clinical trials:

(show top 50) (show all 613)

# Name Status NCT ID Phase Drugs
1 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4 dexmedetomidine
2 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
3 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
4 The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy Unknown status NCT01256021 Phase 4 Botulinum Toxin Type A
5 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Unknown status NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
6 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
7 Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases Unknown status NCT00796380 Phase 4 Xingnaojing
8 Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy Completed NCT01276015 Phase 4 Botulinum Toxin Type A
9 Alterations of Functional Activities and Leg Stiffness After Hamstring Lengthening in Cerebral Palsy Children Completed NCT00154830 Phase 4
10 Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Completed NCT01860196 Phase 4 Meditoxin;Normal saline
11 Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies Completed NCT00964639 Phase 4 Ropivacaine;Saline
12 Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4 Botulinum toxin type A (Botox);placebo (saline)
13 Recurrent Crying Spells in Cerebral Palsy Completed NCT01955655 Phase 4 Baclofen
14 Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth Completed NCT00120588 Phase 4 magnesium
15 Post Marketing Surveillance Study of Dysport Completed NCT00210431 Phase 4
16 Effect of Erythropoietin on Preterm Brain Injury Completed NCT02036073 Phase 4 recombinant human erythropoietin
17 Effectiveness of Robotic Gait Training and Physical Therapy for Children and Youth With Cerebral Palsy Recruiting NCT02391324 Phase 4
18 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4 botox;placebo
19 Synbiotic, Prebiotics and Probiotics in Children With Cerebral Palsy and Constipation Recruiting NCT03117322 Phase 4
20 A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging Recruiting NCT02633241 Phase 4 Dexmedetomidine-Propofol
21 Intrathecal Baclofen (ITB) Delivery Location and Its Effect on Spasticity Recruiting NCT02903823 Phase 4 Baclofen bolus injection
22 Changes of Gas Values in Cord Blood Versus Time and Temperature Not yet recruiting NCT02785367 Phase 4
23 Improvement After Botulinum Toxin Injections to the Arms in Children With Cerebral Palsy Terminated NCT00549471 Phase 4
24 Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy Withdrawn NCT01386255 Phase 4 Baclofen;placebo
25 Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below 15 Years Unknown status NCT01832454 Phase 2, Phase 3
26 Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy Unknown status NCT01489904 Phase 2, Phase 3
27 Targeted Hip Strength Training in Children With Cerebral Palsy (CP) Unknown status NCT01633736 Phase 3
28 Modulation of Brain Plasticity After Perinatal Stroke Unknown status NCT01189058 Phase 2, Phase 3
29 Magnesium Sulfate to Prevent Brain Injury in Premature Infants Unknown status NCT00065949 Phase 3 magnesium sulfate
30 Phase III Clinical Trial of "Botulax®" to Treat Children With Cerebral Palsy Completed NCT01787344 Phase 3 Botulinum Toxin Type A(Botox®);Botulinum toxin type A(Botulax®)
31 Orthotics in Ambulatory Cerebral Palsy Completed NCT01527162 Phase 3
32 Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy Completed NCT00261131 Phase 3 Botulinum Toxin A
33 Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Patients With Cerebral Paralysis Completed NCT01929434 Phase 3
34 The Post-Operative Pain in Cerebral Palsy (POPPIES) Trial Completed NCT01437644 Phase 3 botulinum toxin intramuscular injection
35 Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy Completed NCT01893411 Phase 3 IncobotulinumtoxinA (16 Units per kg body weight);IncobotulinumtoxinA (12 Units per kg body weight);IncobotulinumtoxinA (4 Units per kg body weight)
36 Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy Completed NCT01905683 Phase 3 IncobotulinumtoxinA (16-20 Units per kg body weight)
37 Dutch National ITB Study in Children With Cerebral Palsy Completed NCT00367068 Phase 3 baclofen, intrathecal
38 Static and Dynamic Postural Stability in Cerebral Palsy Children Completed NCT01799304 Phase 3
39 Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions Completed NCT00491894 Phase 3 Oral Glycopyrrolate Liquid
40 A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years Completed NCT01898520 Phase 3 Sativex;Placebo
41 Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles Completed NCT00133861 Phase 2, Phase 3 Botulinum toxin
42 Dysport® Pediatric Lower Limb Spasticity Follow-on Study Completed NCT01251380 Phase 3 Botulinum type A toxin (Dysport®)
43 Dysport® Pediatric Lower Limb Spasticity Study Completed NCT01249417 Phase 3 Botulinum type A toxin (Dysport®);Placebo
44 Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) Completed NCT00014989 Phase 3 magnesium sulfate
45 Individualized Neurodevelopmental Treatment Completed NCT00922077 Phase 3
46 MEOPA to Improve Physical Therapy Results After Multilevel Surgery Completed NCT00632528 Phase 3 MEOPA;Medicinal air
47 Calcium Channel Blockers Compared to Magnesium Sulfate in Fetal Cerebral Blood Flow Completed NCT02591004 Phase 2, Phase 3 Magesium sulphate;Nifedipine
48 BOTOX® Treatment in Pediatric Lower Limb Spasticity Completed NCT01603628 Phase 3 Normal Saline (Placebo)
49 BOTOX® Treatment in Pediatric Upper Limb Spasticity Completed NCT01603602 Phase 3 Normal Saline (Placebo)
50 Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight Completed NCT00114543 Phase 3

Search NIH Clinical Center for Cerebral Palsy

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cerebral Palsy cell therapies at LifeMap Discovery.

Genetic Tests for Cerebral Palsy

Genetic tests related to Cerebral Palsy:

# Genetic test Affiliating Genes
1 Cerebral Palsy 28

Anatomical Context for Cerebral Palsy

MalaCards organs/tissues related to Cerebral Palsy:

38
Brain, Bone, Testes, Spinal Cord, Heart, Tongue, Lung
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cerebral Palsy:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Cerebral Palsy

Articles related to Cerebral Palsy:

(show top 50) (show all 1555)
# Title Authors Year
1
A heel-strike real-time auditory feedback device to promote motor learning in children who have cerebral palsy: a pilot study to test device accuracy and feasibility to use a music and dance-based learning paradigm. ( 29423260 )
2018
2
Deep brain stimulation for dystonia due to cerebral palsy: A review. ( 29396170 )
2018
3
Cognitive functioning in dyskinetic cerebral palsy: Its relation to motor function, communication and epilepsy. ( 29108712 )
2018
4
The treatment of femoral fractures in children with cerebral palsy. ( 29446787 )
2018
5
Deep brain stimulation in cerebral palsy: Time for dynamism in a static encephalopathy. ( 29447767 )
2018
6
Relationship between radiographic patella-alta pathology and walking dysfunction in children with bilateral spastic Cerebral Palsy. ( 29149666 )
2018
7
Comparison of calf muscle architecture between Asian children with spastic cerebral palsy and typically developing peers. ( 29304114 )
2018
8
Contribution of perinatal conditions to cerebral palsy in Uganda. ( 29433660 )
2018
9
Bike skills training for children with cerebral palsy: protocol for a randomised controlled trial. ( 29431140 )
2018
10
Intrathecal baclofen in dyskinetic cerebral palsy: effects on function and activity. ( 29148568 )
2018
11
Commentary Regarding "Caregiver Perceptions and Health-Related Quality-of-Life Changes in Cerebral Palsy Patients After Spinal Arthrodesis". ( 29438220 )
2018
12
Identification of a candidate enhancer for DMRT3 involved in spastic cerebral palsy pathogenesis. ( 29305858 )
2018
13
Knee contracture in children with cerebral palsy: association with muscle lengths. ( 29451692 )
2018
14
Neuroprotective effect of tanshinone IIA weakens spastic cerebral palsy through inflammation, p38MAPK and VEGF in neonatal rats. ( 29257210 )
2018
15
<i>TSEN54</i> Gene-Related Pontocerebellar Hypoplasia Type 2 Could Mimic Dyskinetic Cerebral Palsy with Severe Psychomotor Retardation. ( 29410950 )
2018
16
Estimating medial gastrocnemius muscle volume in children with spastic cerebral palsy: a cross-sectional investigation. ( 29067675 )
2018
17
The Relationship Between Hand Function and Overlapping Motor Representations of the Hands in the Contralesional Hemisphere in Unilateral Spastic Cerebral Palsy. ( 29303031 )
2018
18
Changes in Tactile Function During Intensive Bimanual Training in Children With Unilateral Spastic Cerebral Palsy. ( 29433419 )
2018
19
It is a long road to inclusive education for children with cerebral palsy. ( 29443388 )
2018
20
Pharmacological and neurosurgical interventions for managing dystonia in cerebral palsy: a systematic review. ( 29405267 )
2018
21
Validation of reaching in a virtual environment in typically developing children and children with mild unilateral cerebral palsy. ( 29427357 )
2018
22
Determine the Relationship Between Abdominal Muscle Strength, Trunk Control and Urinary Incontinence in Children with Diplegic Cerebral Palsy. ( 29427287 )
2018
23
Virtual reality training for children with unilateral cerebral palsy. ( 29442357 )
2018
24
Five and 10 minute Apgar scores and risks of cerebral palsy and epilepsy: population based cohort study in Sweden. ( 29437691 )
2018
25
The continually changing epidemiology of cerebral palsy. ( 29430775 )
2018
26
Severity of cerebral palsy and likelihood of adverse events after botulinum toxin A injections. ( 29451702 )
2018
27
Re-engineering the interpretation of electronic fetal monitoring to identify reversible risk for cerebral palsy: a case control series. ( 29447043 )
2018
28
Functional capacity in adults with cerebral palsy: Lower limb muscle strength matters. ( 29438658 )
2018
29
Management of hypertonia in cerebral palsy. ( 29135566 )
2018
30
Family adaptation to cerebral palsy in adolescents: A European multicenter study. ( 28087202 )
2017
31
Influence of trunk control and lower extremity impairments on gait capacity in children with cerebral palsy. ( 28944697 )
2017
32
Serial Casting as an Adjunct to Botulinum Toxin Type A Treatment in Children With Cerebral Palsy and Spastic Paraparesis With Scissoring of the Lower Extremities. ( 28393669 )
2017
33
Neonatal Infection in Children With Cerebral Palsy: A Registry-Based Cohort Study. ( 29428154 )
2017
34
Long-term therapy with intrathecal baclofen improves quality of life in children with severe spastic cerebral palsy. ( 28237420 )
2017
35
Selective dorsal rhizotomy for the treatment of severe spastic cerebral palsy: efficacy and therapeutic durability in GMFCS grade IV and V children. ( 29116382 )
2017
36
Therapeutic Effect Evaluation of Neuromuscular Electrical Stimulation With or Without Strengthening Exercise on Spastic Cerebral Palsy. ( 28990434 )
2017
37
Body composition, diet, and physical activity: a longitudinal cohort study in preschoolers with cerebral palsy. ( 28077375 )
2017
38
Upper Limb Function, Kinematic Analysis, and Dystonia Assessment in Children With Spastic Diplegic Cerebral Palsy and Periventricular Leukomalacia. ( 28776460 )
2017
39
Standing activity intervention and motor function in a young child with cerebral palsy: A case report. ( 28071965 )
2017
40
First words: speech and language interventions in cerebral palsy. ( 28090650 )
2017
41
Value of botulinum toxin injections preceding a comprehensive rehabilitation period for children with spastic cerebral palsy: a cost-effectiveness study. ( 28949368 )
2017
42
Antibody responses to botulinum neurotoxin type A of toxin-treated spastic equinus children with cerebral palsy: A randomized clinical trial comparing two injection schedules. ( 28385185 )
2017
43
Bony reconstruction of hip in cerebral palsy children Gross Motor Function Classification System levels III to V: a systematic review. ( 28953164 )
2017
44
Effects of gross motor function and manual function levels on performance-based ADL motor skills of children with spastic cerebral palsy. ( 28265171 )
2017
45
Focusing on Participation: A Commentary on "Current Rehabilitation Practices for Children with Cerebral Palsy: Focus and Gaps". ( 28080172 )
2017
46
Lumbosacral Dorsal Rhizotomy for Spastic Cerebral Palsy: A Health Technology Assessment. ( 28757906 )
2017
47
Hyperbaric oxygen therapy is safe and effective for the treatment of sleep disorders in children with cerebral palsy. ( 28079475 )
2017
48
Effect of neurodevelopmental treatment-based physical therapy on the change of muscle strength, spasticity, and gross motor function in children with spastic cerebral palsy. ( 28626301 )
2017
49
Bilateral globus pallidus internus deep brain stimulation for dyskinetic cerebral palsy supports success of cochlear implantation in a 5-year old ex-24A week preterm twin with absent cerebellar hemispheres. ( 28017556 )
2017
50
Immediate effects of quick trunk movement exercise on sit-to-stand movement in children with spastic cerebral palsy: a pilot study. ( 28603369 )
2017

Variations for Cerebral Palsy

ClinVar genetic disease variations for Cerebral Palsy:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ADD3 NM_016824.4(ADD3): c.1100G> A (p.Gly367Asp) single nucleotide variant Pathogenic rs564185858 GRCh37 Chromosome 10, 111882007: 111882007

Expression for Cerebral Palsy

Search GEO for disease gene expression data for Cerebral Palsy.

Pathways for Cerebral Palsy

Pathways related to Cerebral Palsy according to KEGG:

36
# Name Kegg Source Accession
1 GABAergic synapse hsa04727

Pathways related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.26 AP4B1 AP4E1 AP4M1 AP4S1 APOE COL4A1
2
Show member pathways
12.28 AP4B1 AP4E1 AP4M1 AP4S1
3 12.06 IL1B IL6 PLP1 TNF
4 11.87 AP4B1 AP4E1 AP4M1 AP4S1
5 11.84 COL4A1 IL1B IL6 TNF
6
Show member pathways
11.77 APOE F2 IL1B IL6 MTHFR TNF
7 11.75 IL1B IL6 TNF
8 11.66 COL4A1 IL1B IL6 TNF
9 11.65 IL1B IL6 TNF
10 11.63 IL1B IL6 TNF
11 11.6 COL4A1 IL1B IL6 TNF
12 11.55 IL1B IL6 TNF
13
Show member pathways
11.54 IL1B IL6 TNF
14 11.47 IL1B IL6 TNF
15 11.4 IL1B IL6 TNF
16 11.39 IL1B IL6 TNF
17 11.23 IL1B IL6 TNF
18 11.21 IL1B IL6 TNF
19 11.11 IL1B IL6 TNF
20 11.11 APOE IL1B IL6 TNF
21 11.06 IL1B IL6 TNF
22 10.71 COL4A1 IL6 TNF
23 10.68 IL1B IL6
24 10.42 IL1B IL6 MTHFR TNF

GO Terms for Cerebral Palsy

Cellular components related to Cerebral Palsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.92 APOE COL4A1 F2 F5 IL1B IL6
2 endoplasmic reticulum lumen GO:0005788 9.65 APOE COL4A1 F2 F5 IL6
3 trans-Golgi network membrane GO:0032588 9.46 AP4B1 AP4E1 AP4M1 AP4S1
4 endosome lumen GO:0031904 9.26 AP4B1 AP4E1 AP4M1 AP4S1
5 AP-4 adaptor complex GO:0030124 8.92 AP4B1 AP4E1 AP4M1 AP4S1

Biological processes related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 vesicle-mediated transport GO:0016192 9.86 AP4B1 AP4E1 AP4M1 AP4S1
2 cellular protein metabolic process GO:0044267 9.85 APOE F2 F5 IL6
3 positive regulation of interleukin-6 production GO:0032755 9.65 IL1B IL6 TNF
4 locomotory exploration behavior GO:0035641 9.58 APOE GAD1
5 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.57 IL1B TNF
6 negative regulation of lipid storage GO:0010888 9.54 IL6 TNF
7 acute-phase response GO:0006953 9.54 F2 IL6 MBL2
8 negative regulation of platelet activation GO:0010544 9.52 APOE F2
9 positive regulation of chemokine biosynthetic process GO:0045080 9.51 IL1B TNF
10 regulation of establishment of endothelial barrier GO:1903140 9.49 IL1B TNF
11 positive regulation of STAT protein import into nucleus GO:2000366 9.46 F2 IL6
12 protein localization GO:0008104 9.46 AP4B1 AP4E1 AP4M1 AP4S1
13 positive regulation of fever generation GO:0031622 9.43 IL1B TNF
14 positive regulation of phagocytosis GO:0050766 9.43 IL1B MBL2 TNF
15 sequestering of triglyceride GO:0030730 9.4 IL1B TNF
16 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 IL1B TNF
17 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.13 APOE IL1B TNF
18 protein targeting GO:0006605 8.92 AP4B1 AP4E1 AP4M1 AP4S1

Sources for Cerebral Palsy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....